[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shaklee Corporation\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":73},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100634002","acute-amino-acid-response-of-proprietary-beverages-100634002",false,"NCT07534020","Acute Amino Acid Response of Proprietary Beverages","A Randomized, Single-Blind, Crossover Pilot Trial to Assess the Effects of Proprietary Beverages on Amino Acids and Acute Appetite Hormone Response in Healthy Adults","Inclusion Criteria:\n\n1. Males and females, ≥20 to ≤50 years of age.\n2. Body mass index (BMI( ≥18.5 and \\\u003C25.0 kg\u002Fm2.\n3. Self-reported regular consumer (≥5 days\u002Fweek) of breakfast.\n4. Women who are either pre- or post-menopausal. Premenopausal women that are not using hormonal contraceptives must have a history of regular menstrual cycles (21-35 d per cycle or at the investigator's discretion) for at least 3 months prior.\n5. Willing to use personal smart phone and capable of downloading the Cronometer app for diet records.\n6. Willing to adhere to all study procedures, including lifestyle considerations, and sign forms providing informed consent to participate in the study and authorization to release relevant protected health information to the Clinical Investigator.\n\nExclusion Criteria:\n\n1. Is currently following, or planning to be on, a weight loss regimen at any time prior to or during the study.\n2. Weight loss or gain \\>4.5 kg within 90 days.\n3. History of gastrointestinal surgery for weight reducing purposes.\n4. History of an eating disorder (e.g., anorexia nervosa or bulimia nervosa, binge eating) or extreme dietary habits (e.g., ketogenic, very high protein, very high fiber, vegan, vegetarian) at the discretion of the Clinical Investigator.\n5. History of unconventional sleep patterns (e.g., night shift) or a diagnosed sleep disorder or chronic medical condition that may impact appetite (in the judgment of the Investigator).\n6. Use of tobacco\u002Fnicotine products (e.g., cigarette smoking, vaping, chewing tobacco) within 12 months.\n7. Use of hemp\u002Fmarijuana products within 60 days. Occasional use (e.g., once or twice a month) within 60 days is allowed.\n8. Unstable use of any prescription medication, where stable use is defined as no change in dose or medication type within 90 days.\n9. Unstable use (initiation or change in dose) within 30 days of hormonal contraceptives.\n10. Use of any dietary supplements, except for a conventional once daily multivitamin\u002Fmineral supplement.\n11. Recent history of (within 12 months) or strong potential for alcohol or substance abuse.\n12. Exposed to any non-registered drug product within 30 days prior.\n13. A score of \\\u003C7 on the Vein Access Scale Assessment.\n14. History or presence, on the basis of the medical history or screening labs, of clinically important cardiac, renal, hepatic, endocrine (including diabetes mellitus), pulmonary, gastrointestinal, biliary, pancreatic, or neurological disorders that may affect the participant's ability to adhere to the study protocol and\u002For affect study outcomes, in the judgment of the Investigator.\n15. Uncontrolled hypertension (systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg).\n16. Known allergy to any ingredients contained in the study product or study foods.\n17. Any signs or symptoms of active infection of clinical relevance (e.g., urinary tract or respiratory) within 5 days.\n18. History or presence of cancer in the prior 2 years, except for nonmelanoma skin cancer.\n19. History of any major trauma or major surgical event within 2 months.\n20. Female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential with unstable use (initiation or change in dose within 30 days) of sex hormones for contraception.\n21. An employee or representative who has a financial interest in Shaklee Corporation.\n22. Any condition the Investigator believes would interfere with the participant's ability to provide informed consent or comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk.",true,"ALL","20 Years","50 Years",{"count":21,"type":22},24,"ESTIMATED","INTERVENTIONAL",[25],"NA","The primary objective of this study is to evaluate post-meal amino acid in response to a proprietary beverages in generally healthy adults.",[28],"Healthy",[30,31,32,33],"postprandial amino acids","appetite","beverages","healthy adults","RECRUITING","2026-04-20",{"date":37,"type":38},"2026-04-23","ACTUAL",{"date":40,"type":38},"2026-04-03",{"date":42,"type":22},"2026-05",{"name":44,"class":45},"Shaklee Corporation","INDUSTRY",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":16,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100625919","nicotinamide-adenine-dinucleotide-responses-to-a-nutritional-supplement-100625919","NCT07428889","Nicotinamide Adenine Dinucleotide Responses to a Nutritional Supplement","A Randomized, Controlled, Pilot Trial to Assess the Effects of a Proprietary Nutritional Supplement on Nicotinamide Adenine Dinucleotide (NAD+) Responses in Healthy Adults","Inclusion Criteria:\n\n1. Males and females, ≥45 to ≤65 years of age\n2. BMI ≥18.5 and \\\u003C30.0 kg\u002Fm2\n3. Ambulatory and currently free of injury or other physical impairment that hinders mobility.\n4. Willing to use personal smart phone with operating system (Android version 12.0 or newer; iOS version 16 or newer).\n5. Willingness to maintain current skin care regimen and avoid any skin-related medical procedures.\n6. Willing to adhere to all study procedures, including lifestyle considerations and sign forms providing informed consent to participate in the study and authorization to release relevant protected health information to the Clinical Investigator.\n\nExclusion Criteria:\n\n1. Is currently following, or planning to be on, a weight loss regimen.\n2. Weight loss or gain \\>4.5 kg.\n3. History of gastrointestinal surgery for weight reducing purposes.\n4. History of an eating disorder (e.g., anorexia nervosa or bulimia nervosa, binge eating) at the discretion of the Clinical Investigator.\n5. History of neurologic disorder that could produce cognitive deterioration.\n6. History of bouts of delirium, confusion, repeated minor head injury or a single injury.\n7. History of unconventional sleep patterns or a diagnosed sleep disorder.\n8. History of any infective or inflammatory brain disease.\n9. Use of tobacco\u002Fnicotine products.\n10. Use of hemp\u002Fmarijuana products.\n11. Unstable use of any prescription medication.\n12. Unstable use (initiation or change in dose) of hormonal contraceptives or therapy.\n13. Use of any dietary supplements (orally or infused), other than a conventional once daily multi-vitamin.\n14. Use of medication(s) or dietary supplement(s) known to affect absorption.\n15. Recent history of or strong potential for alcohol or substance abuse.\n16. Exposed to any non-registered drug product.\n17. A score of \\\u003C7 on the Vein Access Scale Assessment.\n18. History or presence, on the basis of the medical history or screening labs, of clinically important cardiac, renal, hepatic, endocrine (including diabetes mellitus), pulmonary, gastrointestinal, biliary, pancreatic, or neurological disorders.\n19. Uncontrolled hypertension.\n20. Known allergy to any ingredients contained in the study product.\n21. Any signs or symptoms of active infection of clinical relevance.\n22. History or presence of cancer in the prior 2 years, except for non-melanoma skin cancer.\n23. History of any major trauma or major surgical event.\n24. Female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential with unstable use of sex hormones for contraception.\n25. An employee or representative who has a financial interest in Sponsor organization.","45 Years","65 Years",{"count":56,"type":22},34,[25],"The objective of this study is to evaluate nicotinamide adenine dinucleotide (NAD+) in response to a proprietary nutritional supplement in generally healthy adults, compared to placebo.",[60],"Healthy Adult",[62,63],"NAD+ metabolism","Markers of health","2026-04-09",{"date":66,"type":38},"2026-04-13",{"date":68,"type":38},"2026-02-17",{"date":70,"type":22},"2026-06",{"name":44,"class":45},1,""]